B19V is a widespread human pathogen that displays a remarkable specificity for erythroid progenitors. There are only a few semi-permissive cell lines for B19V, such as UT7/Epo-S1 (8) and KU812Ep6 (7) cells. Recently, we reported that ex vivo-generated CD36 + erythroid progenitor cells (EPCs) were highly permissive to B19V infection (10) . To date, the preferential B19V propagation in erythroid progenitors is not fully understood. Capsid protein synthesis appears to be restricted to permissive erythroid progenitors, but nonstructural protein 1 (NS1) is produced in both permissive and nonpermissive cells (6, 9) . Here, we investigated the expression profile of B19V proteins in permissive and nonpermissive cells, and demonstrated that codon optimization significantly improved B19V capsid expression in nonpermissive cells.
To analyze the expression profile of B19V genes, we constructed six plasmids carrying the genes encoding VP1, VP2, NS1, 11-kDa, and 7.5-kDa proteins, and a putative protein X, respectively (11) (Fig. 1A) . Each corresponding open reading frame (ORF) was PCR-amplified and cloned into a pCMV-3Tag-6 vector (Invitrogen, Carlsbad, CA) to generate Flag-tagged proteins. After transfection of the plasmids into permissive (CD36 + EPC), semipermissive (UT7/Epo-S1), and nonpermissive (293T and HeLa) cells, the levels of protein synthesis were assessed by immunoblotting at 48-h post-transfection (hpt) using anti-Flag M2 antibody (Sigma.
Louis, MO) (Fig. 1B) . VP1 and VP2 expression levels were high in CD36 + EPCs, very low in UT7/Epo-S1 and 293T cells, and undetectable in HeLa cells (Fig. 1B) . In contrast, NS1, 11-kDa, 7.5-kDa, and X proteins were highly produced in all cells tested.
Codon usage bias has been reported for numerous organisms, from viruses (1) Fig.1 ). To further elucidate cis-elements that may influence the expression of VP2, we constructed eight plasmids using codon-optimized VP2 (optVP2) and wild-type VP2 (VP2).
Briefly, VP2 or optVP2 genes with or without the 3'UTR (nt 4970 to 5409) of the B19V VP2
gene were inserted into a pcDNA(p6) vector in which a CMV promoter of pcDNA3.1 (Invitrogen) was replaced with a B19V p6 promoter (p6, nt 188 to 584) ( Fig. 2A ). Likewise, VP2
or optVP2 with or without the 3'UTR were inserted into into pcDNA3.1 in which expression of B19V capsid gene was controlled by the CMV promoter (pCMV) ( Figure 2C and 2D, optVP2 expression in 293T cells and CD36 + EPCs was comparable, indicating that VP2 production was dramatically enhanced by codon optimization. A similar enhancement has been reported for various genes in a variety of viruses, including human herpesvirus (2), papillomavirus (3), hepatitis A virus (1) and hepatitis C virus (4). We observed a decreased VP2 production when the plasmids carrying VP2 or optVP2 with B19V 3'UTR were utilized. This B19V 3'UTR-related inhibition of VP2 production was particularly apparent in UT7/Epo-S1 and HeLa cells but not obvious in 293T, CD34 + HSCs, and on November 13, 2017 by guest http://jvi.asm.org/ Downloaded from CD36 + EPCs. Additionally, B19V 3'UTR-related inhibition appeared to be greater in the context of the pCMV-controlled transcription than that of p6. This finding suggests that the negative impact of B19V 3'UTR on capsid production was promoter-and cell types-dependent.
To generate empty B19 virus-like particles (VLPs) composed of optVP1 and optVP2, a B19V optVP1 gene was synthesized in the same manner as described for optVP2. Both of optVP1 and optVP2 were subcloned into a pIRES-bicistronic expression vector (Clonetech), resulting in pIRES-optVP2/optVP1. To adjust the VP1/VP2 ratio, an inverted-repeat (ITR, 5'-GGATCCCGACGATCC-3') sequence was inserted immediately upstream of optVP1 (Fig. 3A) .
When 293T cells were transfected with individual plasmids, overall VP2 production levels were similar among the three samples (Fig. 3B) . The VP1/VP2 ratio was 1:5 or 1:20 in the cells transfected with pIRES-optVP2/optVP1 or pIRES-optVP2-ITR-optVP1, respectively, showing that the VP1/VP2 (1:20) ratio of the natural B19V capsid was obtained by the ITR insertion. By IF assay, B19V capsid proteins were detected predominantly in nuclei at 24 hpt (Fig. 3C) . Next, we attempted to generate B19-VLPs in 293T cells using pIRES-optVP2-ITR-optVP1 by which the natural VP1/VP2 ratio was obtained. When cell lysates were subjected to sequential sedimentation in sucrose and CsCl, banding of parvovirus proteins was detected at 1.31 g/ml (density of empty capsid), and VP1 and VP2 were detected by immunoblotting (Fig. 3D) . Direct electron microscopy of the sample revealed typical parvovirus-like particles (Fig. 3E ).
In summary, we demonstrate cell type-specific expression of B19V capsid proteins and a dramatic increase in capsid protein production in nonpermissive cells by codon optimization.
Using the optVP1 and optVP2 genes, empty B19-VLPs were generated in 293T cells. Although further studies are required for optimal production of B19-VLPs, our current work provides new insight for B19V research using nonpermissive cells and may be of practical importance in vaccine development. 
